Korean Journal of Biological Psychiatry (생물정신의학)

The Korean Society of Biological Psychiatry (대한생물정신의학회)
권호 표지

Relationship between Serum Inflammatory Marker and Psychotic Symptoms in Inpatients with Schizophrenia or Schizoaffective Disorder

조현병 및 조현정동장애 입원환자에서 혈청 염증표지자와 정신병적 증상과의 관련성

  • Kim, Kye Hwan (Department of Psychiatry, Gongju National Hospital) ;
  • Lee, Kounseok (Department of Psychiatry, Gongju National Hospital) ;
  • Kim, Su Jin (Neuropsychiatry Research Laboratory, Gongju National Hospital) ;
  • Lee, Eun Kyu (Department of Psychiatry, Gongju National Hospital) ;
  • Song, Yul-Mai (Neuropsychiatry Research Laboratory, Gongju National Hospital) ;
  • Park, Jin Young (Department of Psychiatry, Yonsei University College of Medicine)
  • 김계환 (국립공주병원 정신건강의학과) ;
  • 이건석 (국립공주병원 정신건강의학과) ;
  • 김수진 (국립공주병원 뇌기능연구소) ;
  • 이은규 (국립공주병원 정신건강의학과) ;
  • 송열매 (국립공주병원 뇌기능연구소) ;
  • 박진영 (연세대학교 의과대학 정신과학교실)
  • Received : 2012.06.27
  • Accepted : 2012.08.14
  • Published : 2012.11.30
Download PDF
⟨ Previous Next ⟩

Abstract

Objectives Despite the growing research interest in the role of immunological markers in schizophrenia, a few studies, with conflicting results, have focused on the association between high sensitivity C-reactive protein (hs-CRP) levels and clinical characteristics in schizophrenia. The aim of the present study was to examine the association of serum hs-CRP with psychopathology in schizophrenia. Methods Fifty-five inpatients with schizophrenia or schizoaffective disorder were enrolled. Serum levels of hs-CRP were measured, and each patient was assessed with the Korean version of the Positive and Negative Syndrome Scale (PANSS). Results In correlation analysis of hs-CRP with PANSS subscales, positive subscale score has significant positive correlation (r = 0.271, p = 0.046). In independent t-test analysis, subjects with hs-CRP > 0.3 mg/dL (elevated CRP group, n = 43) had significantly higher PANSS positive subscale score (t = -3.273, df = 24.107, p = 0.003) than those with hs-CRP ${\leq}$ 0.3 mg/dL (normal CRP group, n = 12). Conclusions Elevated serum levels of high sensitivity C-reactive protein in schizophrenia are associated with the severity of psychotic symptoms.

Keywords

References

  1. Yolken RH, Torrey EF. Viruses, schizophrenia, and bipolar disorder. Clin Microbiol Rev 1995;8:131-145.
  2. Maes M, Bocchio Chiavetto L, Bignotti S, Battisa Tura GJ, Pioli R, Boin F, et al. Increased serum interleukin-8 and interleukin-10 in schizophrenic patients resistant to treatment with neuroleptics and the stimulatory effects of clozapine on serum leukemia inhibitory factor receptor. Schizophr Res 2002;54:281-291. https://doi.org/10.1016/S0920-9964(00)00094-3
  3. Muller N, Riedel M, Gruber R, Ackenheil M, Schwarz MJ. The immune system and schizophrenia. An integrative view. Ann N Y Acad Sci 2000;917:456-467.
  4. Rapaport MH, Lohr JB. Serum-soluble interleukin-2 receptors in neuroleptic-naive schizophrenic subjects and in medicated schizophrenic subjects with and without tardive dyskinesia. Acta Psychiatr Scand 1994;90:311-315. https://doi.org/10.1111/j.1600-0447.1994.tb01599.x
  5. Sirota P, Meiman M, Herschko R, Bessler H. Effect of neuroleptic administration on serum levels of soluble IL-2 receptor-alpha and IL-1 receptor antagonist in schizophrenic patients. Psychiatry Res 2005;134:151-159. https://doi.org/10.1016/j.psychres.2004.04.012
  6. Sadock BJ, Kaplan HI, Sadock VA. Kaplan & Sadock's Synopsis of Psychiatry: Behavioral Sciences/Clinical Psychiatry. 10th ed. Philadelphia: Lippincott Williams & Wilkins;2007. p.467-497.
  7. Lin A, Kenis G, Bignotti S, Tura GJ, De Jong R, Bosmans E, et al. The inflammatory response system in treatment-resistant schizophrenia: increased serum interleukin-6. Schizophr Res 1998;32:9-15. https://doi.org/10.1016/S0920-9964(98)00034-6
  8. Naudin J, Capo C, Giusano B, Mege JL, Azorin JM. A differential role for interleukin-6 and tumor necrosis factor-alpha in schizophrenia? Schizophr Res 1997;26:227-233. https://doi.org/10.1016/S0920-9964(97)00059-5
  9. Licinio J, Seibyl JP, Altemus M, Charney DS, Krystal JH. Elevated CSF levels of interleukin-2 in neuroleptic-free schizophrenic patients. Am J Psychiatry 1993;150:1408-1410. https://doi.org/10.1176/ajp.150.9.1408
  10. el-Mallakh RS, Suddath RL, Wyatt RJ. Interleukin-1 alpha and interleukin- 2 in cerebrospinal fluid of schizophrenic subjects. Prog Neuropsychopharmacol Biol Psychiatry 1993;17:383-391. https://doi.org/10.1016/0278-5846(93)90072-Z
  11. Rapaport MH, McAllister CG, Pickar D, Tamarkin L, Kirch DG, Paul SM. CSF IL-1 and IL-2 in medicated schizophrenic patients and normal volunteers. Schizophr Res 1997;25:123-129. https://doi.org/10.1016/S0920-9964(97)00008-X
  12. McAllister CG, van Kammen DP, Rehn TJ, Miller AL, Gurklis J, Kelley ME, et al. Increases in CSF levels of interleukin-2 in schizophrenia: effects of recurrence of psychosis and medication status. Am J Psychiatry 1995;152:1291-1297. https://doi.org/10.1176/ajp.152.9.1291
  13. Muller N, Riedel M, Scheppach C, Brandstatter B, Sokullu S, Krampe K, et al. Beneficial antipsychotic effects of celecoxib add-on therapy compared to risperidone alone in schizophrenia. Am J Psychiatry 2002;159:1029-1034. https://doi.org/10.1176/appi.ajp.159.6.1029
  14. Rapaport MH, Delrahim KK, Bresee CJ, Maddux RE, Ahmadpour O, Dolnak D. Celecoxib augmentation of continuously ill patients with schizophrenia. Biol Psychiatry 2005;57:1594-1596. https://doi.org/10.1016/j.biopsych.2005.02.024
  15. Zhang XY, Zhou DF, Cao LY, Zhang PY, Wu GY, Shen YC. Changes in serum interleukin-2, -6, and -8 levels before and during treatment with risperidone and haloperidol: relationship to outcome in schizophrenia. J Clin Psychiatry 2004;65:940-947. https://doi.org/10.4088/JCP.v65n0710
  16. Zakharyan R, Chavushyan A, Khoyetsyan A, Stahelova A, Arakelyan A, Boyajyan A, et al. Genetic variants of the inflammatory C-reactive protein and schizophrenia in Armenian population: a pilot study. Int J Immunogenet 2010;37:407-410. https://doi.org/10.1111/j.1744-313X.2010.00942.x
  17. Meyer JM, McEvoy JP, Davis VG, Goff DC, Nasrallah HA, Davis SM, et al. Inflammatory markers in schizophrenia: comparing antipsychotic effects in phase 1 of the clinical antipsychotic trials of intervention effectiveness study. Biol Psychiatry 2009;66:1013-1022. https://doi.org/10.1016/j.biopsych.2009.06.005
  18. Lowe GD. Circulating inflammatory markers and risks of cardiovascular and non-cardiovascular disease. J Thromb Haemost 2005;3:1618-1627. https://doi.org/10.1111/j.1538-7836.2005.01416.x
  19. Bassuk SS, Rifai N, Ridker PM. High-sensitivity C-reactive protein: clinical importance. Curr Probl Cardiol 2004;29:439-493.
  20. Pfutzner A, Forst T. High-sensitivity C-reactive protein as cardiovascular risk marker in patients with diabetes mellitus. Diabetes Technol Ther 2006;8:28-36. https://doi.org/10.1089/dia.2006.8.28
  21. Akanji AO, Ohaeri JU, Al-Shammri S, Fatania HR. Association of blood levels of C-reactive protein with clinical phenotypes in Arab schizophrenic patients. Psychiatry Res 2009;169:56-61. https://doi.org/10.1016/j.psychres.2008.06.010
  22. Fawzi MH, Fawzi MM, Fawzi MM, Said NS. C-reactive protein serum level in drug-free male Egyptian patients with schizophrenia. Psychiatry Res 2011;190:91-97. https://doi.org/10.1016/j.psychres.2011.05.010
  23. Dickerson F, Stallings C, Origoni A, Boronow J, Yolken R. C-reactive protein is associated with the severity of cognitive impairment but not of psychiatric symptoms in individuals with schizophrenia. Schizophr Res 2007;93:261-265. https://doi.org/10.1016/j.schres.2007.03.022
  24. Schattner A, Cori Y, Hahn T, Sirota P. No evidence for autoimmunity in schizophrenia. J Autoimmun 1996;9:661-666. https://doi.org/10.1006/jaut.1996.0086
  25. Coe CL, Love GD, Karasawa M, Kawakami N, Kitayama S, Markus HR, et al. Population differences in proinflammatory biology: Japanese have healthier profiles than Americans. Brain Behav Immun 2011;25:494-502. https://doi.org/10.1016/j.bbi.2010.11.013
  26. Fan X, Pristach C, Liu EY, Freudenreich O, Henderson DC, Goff DC. Elevated serum levels of C-reactive protein are associated with more severe psychopathology in a subgroup of patients with schizophrenia. Psychiatry Res 2007;149:267-271. https://doi.org/10.1016/j.psychres.2006.07.011
  27. Yi JS, Ahn YM, Shin HK, An SK, Joo YH, Kim SH, et al. Reliability and validity of the Korean version of the Positive and Negative Syndrome Scale. J Korean Neuropsychiatr Assoc 2001;40:1090-1105.
  28. Mazzarello V, Cecchini A, Fenu G, Rassu M, Dessy LA, Lorettu L, et al. Lymphocytes in schizophrenic patients under therapy: serological, morphological and cell subset findings. Ital J Anat Embryol 2004;109:177-188.
  29. Maes M, Bocchio Chiavetto L, Bignotti S, Battisa Tura G, Pioli R, Boin F, et al. Effects of atypical antipsychotics on the inflammatory response system in schizophrenic patients resistant to treatment with typical neuroleptics. Eur Neuropsychopharmacol 2000;10:119-124.
  30. Bachneff SA. Regional cerebral blood flow in schizophrenia and the local circuit neurons hypothesis. Schizophr Bull 1996;22:163-182. https://doi.org/10.1093/schbul/22.1.163
  31. Shinba T, Nagano M, Kariya N, Ogawa K, Shinozaki T, Shimosato S, et al. Near-infrared spectroscopy analysis of frontal lobe dysfunction in schizophrenia. Biol Psychiatry 2004;55:154-164. https://doi.org/10.1016/S0006-3223(03)00547-X
  32. Hanson DR, Gottesman II. Theories of schizophrenia: a genetic-inflammatory-vascular synthesis. BMC Med Genet 2005;6:7.
  33. Lee SG, Choi JH, Lee DS, Jang SH, Kim JJ, Kim KB, et al. Correlations between serum C-Reactive Protein levels and symptoms of bipolar mania and schizophrenia. J Soc Korean Women Psychiatr 2011;9:45-52.
  34. Naudin J, Mege JL, Azorin JM, Dassa D. Elevated circulating levels of IL-6 in schizophrenia. Schizophr Res 1996;20:269-273. https://doi.org/10.1016/0920-9964(96)00014-X
  35. Zhang XY, Zhou DF, Zhang PY, Wu GY, Cao LY, Shen YC. Elevated interleukin-2, interleukin-6 and interleukin-8 serum levels in neuroleptic-free schizophrenia: association with psychopathology. Schizophr Res 2002;57:247-258. https://doi.org/10.1016/S0920-9964(01)00296-1
  36. Akiyama K. Serum levels of soluble IL-2 receptor alpha, IL-6 and IL-1 receptor antagonist in schizophrenia before and during neuroleptic administration. Schizophr Res 1999;37:97-106. https://doi.org/10.1016/S0920-9964(98)00140-6
  37. Maes M, Bosmans E, Calabrese J, Smith R, Meltzer HY. Interleukin-2 and interleukin-6 in schizophrenia and mania: effects of neuroleptics and mood stabilizers. J Psychiatr Res 1995;29:141-152. https://doi.org/10.1016/0022-3956(94)00049-W
  38. Yolken RH, Torrey EF. Viruses, schizophrenia, and bipolar disorder. Clin Microbiol Rev 1995;8:131-145.